TCRT earnings: next report 2026-08-18, real EPS beat/miss history, analyst consensus Hold, P/E -0.90. Updated 2026-07-23.
Alaunos Therapeutics (TCRT) Research Hub
Alaunos Therapeutics (TCRT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.51 USD (-3.21%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.90, market cap 0.00B. This hub links to the full technical, earnings and options research available for TCRT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.51 USD (-3.21%) |
| 52-week range | 1.49 USD – 2.44 USD |
| Trend regime | Range |
| 14-day RSI | 14.7 (Oversold) |
| Trailing P/E | -0.90 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-18 |
Available research for TCRT
Covered Call on TCRT: how it works, illustrative setup around the real 1.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TCRT: how it works, illustrative setup around the real 1.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TCRT: how it works, illustrative setup around the real 1.51 USD price, max profit/loss, breakeven and when to use it. Educational.
TCRT technical analysis: range, last 1.51 USD, RSI 14.7, 52w range 1.49 USD–2.44 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TCRT in?
Alaunos Therapeutics (TCRT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TCRT in an uptrend or downtrend?
As of 2026-09-11, TCRT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TCRT's trailing P/E ratio?
TCRT's trailing P/E is -0.90, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does TCRT next report earnings?
TCRT is next scheduled to report earnings on 2026-08-18.